Pharma / Pharmaceutical / Biotech / BioTech / Drugs / Pharmaceuticals / Drug / Boston / Boston blog main / Boston top stories / National blog main / 3E Bioventures Capital / Acetylon / Bristol-myers Squibb / Celgene / clinical trials / Cobro Ventures / Daguang Wang / diabetes / Frank Yan / Life Sciences / Michael Huang / nerve pain / Regenacy Pharmaceuticals / Ricolinostat / Simon Jones / Startup / Ta Ya Venture / Taiwania Capital Management / Venture Capital / Viva Biotech Holdings / Yonjin Capital

Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments

Posted On: Mar 25, 2020   |   Posted By: Xconomy

Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments

Regenacy Pharmaceuticals, a biotech formed as part of Celgene's acquisition of Acetylon Pharmaceuticals in late 2016 , has raised $30 million in Series A financing to move its lead program into a Phase 2 proof-of-concept trial this year. The Waltham, MA-based company is developing treatments to address the underlying cause of peripheral neuropathies-a form of nerve damage in the fingers and toes that causes numbness and tingling-associated with diabetes and other conditions. Regenacy plans to first evaluate its lead drug candidate, ricolinostat, in diabetic peripheral neuropathy. Nerve damage caused by diabetes is a common and serious complication of both type 1...

Continue reading ...